Percentages of tetramer+ CD8 T cells in PBMCs of HHV8-seropositive patients
Clinical group, UPN . | Disease status* . | K12 . | gB . | ORF65 . | ORF6 . | ORF61 . | pp65 . |
---|---|---|---|---|---|---|---|
Cutoff value | 0.26 | 0.17 | 0.18 | 0.26 | 0.16 | 0.24 | |
Group 1: transplant recipients | |||||||
1 | KS- | 0.2 | 0.07 | 0.23 | 0.3 | 0.16 | 2.96 |
2 | KS- | 0.5 | 0.01 | 0.3 | 0.42 | 1.1 | 0.43 |
3 | KS- | 0.12 | 0.09 | 0.32 | 0.41 | 0.08 | 0.12 |
4 | KS- | 0.19 | 0.08 | 0.25 | 0.29 | 0.06 | 0.29 |
5 | KS- | 0.31 | 0.34 | 0.38 | 1.06 | 0.37 | 12.9 |
6 | KS- | 0.27 | 0.17 | 0.38 | 1.4 | 0.38 | 0.06 |
7 | KS- | 0.52 | 0.1 | 0.63 | 0.11 | 0.30 | 0.53 |
8 | KS- | 0.26 | 0.22 | 0.17 | 0.65 | 0.2 | 0.38 |
9 | KSR | 0.59 | 0.3 | 0.28 | 0.03 | 0.70 | 1.72 |
10 | KSR | 0.31 | 0.22 | 0.30 | 0.48 | 0.12 | 0.24 |
11 | KS+ | 1.98 | 2.06 | 2.2 | 1.85 | 0.45 | — |
12 | KS+ | 0.22 | 0.09 | 0.01 | 0.23 | 0.12 | 0.15 |
Group 2: HIV | |||||||
13 | KS+ | 0.18 | 0.24 | 0.23 | 0.11 | 0.05 | 0.02 |
14 | KS+ | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 4.2 |
15 | KS+ | 0.13 | 0.18 | 0.13 | 0.24 | 0.21 | 3.2 |
16 | KS+ | 0.38 | 0.19 | 0.33 | 0.56 | 0.08 | — |
17 | KS+ | 0.04 | 0.00 | 0.02 | 0.13 | 0.04 | 2.75 |
18 | KS+ | 0.31 | 0.14 | 0.26 | 0.34 | 0.13 | — |
19 | KS+ | 0.28 | 0.2 | 0.39 | 0.46 | 0.11 | — |
20 | KSR | 0.08 | 0.01 | 0.01 | 0.02 | 0.07 | 5.65 |
21 | KSR | 0.03 | 0.00 | 0.01 | 0.11 | 0.15 | 5.33 |
22 | KSR | 0.04 | 0.02 | 0.02 | 0.09 | 0.15 | 3.66 |
23 | KSR | 0.09 | 0.03 | 0.01 | 0.06 | 0.03 | 1.00 |
24 | KSR | 0.04 | 0.01 | 0.02 | 0.1 | 0.03 | 0.7 |
25 | KSR | 0.25 | 0.06 | 0.19 | 0.05 | 0.09 | 6.98 |
26 | KSR | 0.01 | 0.00 | 0.01 | 0.13 | 0.24 | 0.95 |
27 | KSR | 0.22 | 0.04 | 0.13 | 0.04 | 0.05 | 0.16 |
28 | KSR | 0.1 | 0.08 | 0.07 | 0.2 | 0.1 | 4.38 |
29 | KSR | 0.11 | 0.03 | 0.06 | 0.06 | 0.02 | 1.3 |
30 | KSR | 0.2 | 0.02 | 0.1 | — | — | 1.23 |
31 | KSR | 0.1 | 0.1 | 0.13 | 0.04 | 0.03 | 0.09 |
32 | KSR | 0.25 | 0.07 | 0.1 | 0.05 | 0.12 | 0.5 |
33 | KSR | 0.37 | 0.07 | 0.1 | 0.03 | 0.05 | 0.02 |
34 | KSR | 0.25 | 0.04 | 0.07 | 0.04 | 0.04 | 2.66 |
35 | KSR | 0.21 | 0.1 | 0.24 | 0.33 | 0.1 | 0.54 |
36 | KSR | 0.2 | 0.16 | 0.2 | 0.26 | 0.17 | 6.00 |
Group 3: classical | |||||||
37 | KS+ | 0.15 | 0.09 | 0.28 | 0.18 | 0.13 | 2.00 |
38 | KS+ | 0.17 | 0.07 | 0.15 | 0.45 | 0.11 | 0.06 |
39 | KS+ | 0.15 | 0.15 | 0.06 | 0.13 | 0.06 | — |
40 | KS+ | 0.2 | 0.14 | 0.21 | 0.28 | 0.38 | 1.29 |
41 | KS+ | 0.13 | 0.3 | 0.17 | 0.22 | 0.31 | 4.64 |
42 | KS+ | 0.52 | 0.62 | 0.57 | 0.49 | 0.39 | 0.31 |
43 | KS+ | 0.07 | 0.21 | 0.2 | 0.53 | 0.03 | 0.11 |
44 | KS+ | 0.35 | 0.2 | 0.65 | 0.35 | 0.32 | 2.85 |
45 | KS+ | 0.11 | 0.4 | 0.1 | 0.07 | 0.08 | 1.48 |
46 | KSR | 0.1 | 0.08 | 0.11 | 0.17 | 0.12 | 0.07 |
47 | KSR | 0.12 | 0.57 | 0.32 | — | — | — |
48 | KSR | 0.31 | 0.45 | 0.4 | 0.93 | 0.2 | 2.39 |
Total patients with positive response, % | 31 | 35 | 50 | 43.5 | 32 | 74 | |
Mean percentage of tetramer+ cells | 0.37 | 0.31 | 0.3 | 0.44 | 0.31 | 2.96 |
Clinical group, UPN . | Disease status* . | K12 . | gB . | ORF65 . | ORF6 . | ORF61 . | pp65 . |
---|---|---|---|---|---|---|---|
Cutoff value | 0.26 | 0.17 | 0.18 | 0.26 | 0.16 | 0.24 | |
Group 1: transplant recipients | |||||||
1 | KS- | 0.2 | 0.07 | 0.23 | 0.3 | 0.16 | 2.96 |
2 | KS- | 0.5 | 0.01 | 0.3 | 0.42 | 1.1 | 0.43 |
3 | KS- | 0.12 | 0.09 | 0.32 | 0.41 | 0.08 | 0.12 |
4 | KS- | 0.19 | 0.08 | 0.25 | 0.29 | 0.06 | 0.29 |
5 | KS- | 0.31 | 0.34 | 0.38 | 1.06 | 0.37 | 12.9 |
6 | KS- | 0.27 | 0.17 | 0.38 | 1.4 | 0.38 | 0.06 |
7 | KS- | 0.52 | 0.1 | 0.63 | 0.11 | 0.30 | 0.53 |
8 | KS- | 0.26 | 0.22 | 0.17 | 0.65 | 0.2 | 0.38 |
9 | KSR | 0.59 | 0.3 | 0.28 | 0.03 | 0.70 | 1.72 |
10 | KSR | 0.31 | 0.22 | 0.30 | 0.48 | 0.12 | 0.24 |
11 | KS+ | 1.98 | 2.06 | 2.2 | 1.85 | 0.45 | — |
12 | KS+ | 0.22 | 0.09 | 0.01 | 0.23 | 0.12 | 0.15 |
Group 2: HIV | |||||||
13 | KS+ | 0.18 | 0.24 | 0.23 | 0.11 | 0.05 | 0.02 |
14 | KS+ | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 4.2 |
15 | KS+ | 0.13 | 0.18 | 0.13 | 0.24 | 0.21 | 3.2 |
16 | KS+ | 0.38 | 0.19 | 0.33 | 0.56 | 0.08 | — |
17 | KS+ | 0.04 | 0.00 | 0.02 | 0.13 | 0.04 | 2.75 |
18 | KS+ | 0.31 | 0.14 | 0.26 | 0.34 | 0.13 | — |
19 | KS+ | 0.28 | 0.2 | 0.39 | 0.46 | 0.11 | — |
20 | KSR | 0.08 | 0.01 | 0.01 | 0.02 | 0.07 | 5.65 |
21 | KSR | 0.03 | 0.00 | 0.01 | 0.11 | 0.15 | 5.33 |
22 | KSR | 0.04 | 0.02 | 0.02 | 0.09 | 0.15 | 3.66 |
23 | KSR | 0.09 | 0.03 | 0.01 | 0.06 | 0.03 | 1.00 |
24 | KSR | 0.04 | 0.01 | 0.02 | 0.1 | 0.03 | 0.7 |
25 | KSR | 0.25 | 0.06 | 0.19 | 0.05 | 0.09 | 6.98 |
26 | KSR | 0.01 | 0.00 | 0.01 | 0.13 | 0.24 | 0.95 |
27 | KSR | 0.22 | 0.04 | 0.13 | 0.04 | 0.05 | 0.16 |
28 | KSR | 0.1 | 0.08 | 0.07 | 0.2 | 0.1 | 4.38 |
29 | KSR | 0.11 | 0.03 | 0.06 | 0.06 | 0.02 | 1.3 |
30 | KSR | 0.2 | 0.02 | 0.1 | — | — | 1.23 |
31 | KSR | 0.1 | 0.1 | 0.13 | 0.04 | 0.03 | 0.09 |
32 | KSR | 0.25 | 0.07 | 0.1 | 0.05 | 0.12 | 0.5 |
33 | KSR | 0.37 | 0.07 | 0.1 | 0.03 | 0.05 | 0.02 |
34 | KSR | 0.25 | 0.04 | 0.07 | 0.04 | 0.04 | 2.66 |
35 | KSR | 0.21 | 0.1 | 0.24 | 0.33 | 0.1 | 0.54 |
36 | KSR | 0.2 | 0.16 | 0.2 | 0.26 | 0.17 | 6.00 |
Group 3: classical | |||||||
37 | KS+ | 0.15 | 0.09 | 0.28 | 0.18 | 0.13 | 2.00 |
38 | KS+ | 0.17 | 0.07 | 0.15 | 0.45 | 0.11 | 0.06 |
39 | KS+ | 0.15 | 0.15 | 0.06 | 0.13 | 0.06 | — |
40 | KS+ | 0.2 | 0.14 | 0.21 | 0.28 | 0.38 | 1.29 |
41 | KS+ | 0.13 | 0.3 | 0.17 | 0.22 | 0.31 | 4.64 |
42 | KS+ | 0.52 | 0.62 | 0.57 | 0.49 | 0.39 | 0.31 |
43 | KS+ | 0.07 | 0.21 | 0.2 | 0.53 | 0.03 | 0.11 |
44 | KS+ | 0.35 | 0.2 | 0.65 | 0.35 | 0.32 | 2.85 |
45 | KS+ | 0.11 | 0.4 | 0.1 | 0.07 | 0.08 | 1.48 |
46 | KSR | 0.1 | 0.08 | 0.11 | 0.17 | 0.12 | 0.07 |
47 | KSR | 0.12 | 0.57 | 0.32 | — | — | — |
48 | KSR | 0.31 | 0.45 | 0.4 | 0.93 | 0.2 | 2.39 |
Total patients with positive response, % | 31 | 35 | 50 | 43.5 | 32 | 74 | |
Mean percentage of tetramer+ cells | 0.37 | 0.31 | 0.3 | 0.44 | 0.31 | 2.96 |
Cutoff value was defined for each tetramer as the mean frequency + 2 SD of tetramer+ cells in 18 HLA-A2- HHV8+ individuals. Responses in patients were considered positive if the percentage of tetramer+ cells was above the cutoff value. Positive values are shown in italics.
UPN indicates unique patient number; and —, not done.
Disease status at time of analysis, defined as patients with ongoing KS (KS+), patients with KS in remission (KSR), and patients without KS lesions (KS-).